Denmark, Novo Nordisk
Novo Nordisk CEO Lars Fruergaard Jorgensen will testify Tuesday before a Senate panel looking into the drug maker's pricing ...
In a high-profile showdown Tuesday with Sen. Bernie Sanders’ Senate health committee, Novo Nordisk CEO Lars Fruergaard ...
The CEO of Novo Nordisk will testify in the Senate HELP Committee tomorrow about the cost of popular diabetes and weight loss ...
Ahead of a Senate hearing centered on high prices for Novo Nordisk’s in-demand semaglutide medications, lawmakers are ...
Ozempic and Wegovy are making so much money for Novo Nordisk A/S that their cumulative sales will soon surpass the ...
On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 ...
Denmark stocks were lower after the close on Monday, as losses in the Healthcare, Chemicals and Personal & Household Goods ...
Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
(Reuters) - Novo Nordisk (NYSE: NVO )'s blockbuster diabetes drug Ozempic will be eligible for U.S. government's price ...